Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:51:54.169Z.
Calculation as of: 2026-10-06T16:51:54.169Z.
Quote observation: 2026-10-06T16:50:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 80f889fb03c5e90f23e6dbb960addb407f240d79d9565bd54dedfb6815f2f0ce
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Heartflow, Inc. Common Stock
Market Cap
$4.41B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.41B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.40B
EV/EBITDA Ratio
8.80x
TTM Avg
11.30x
3Y Avg
25.94x
5Y Avg
24.40x
Market Cap
$4.29B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.63B
EV/EBITDA Ratio
75.94x
TTM Avg
416.98x
3Y Avg
416.98x
5Y Avg
416.98x
Market Cap
$4.66B
EV/EBITDA Ratio
13.99x
TTM Avg
13.23x
3Y Avg
15.13x
5Y Avg
17.95x
Market Cap
$4.67B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.68B
EV/EBITDA Ratio
34.99x
TTM Avg
39.32x
3Y Avg
75.54x
5Y Avg
104.36x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Heartflow, Inc. Common Stock (HTFL) | $4.41B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.41B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.40B | 8.80x | 11.30x | 25.94x | 24.40x |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.29B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.63B | 75.94x | 416.98x | 416.98x | 416.98x |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 13.99x | 13.23x | 15.13x | 17.95x |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.67B | N/A | N/A | N/A | N/A |
| LivaNova PLC (LIVN)vs › | $4.15B | 16.30x | 14.83x | 60.35x | 57.23x |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 34.99x | 39.32x | 75.54x | 104.36x |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.73B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
